Breakthrough Treatment For Early Onset Severe Hemolytic Disease Of The Fetus And Newborn

```html

Johnson & Johnson Announces Positive Results from Phase 2 Unity Study of Nipocalimab

Breakthrough Treatment for Early-Onset Severe Hemolytic Disease of the Fetus and Newborn

WEB SPRING HOUSE, Pa. - August 7, 2024

Johnson & Johnson today announced positive results from the Phase 2 open-label UNITY study of nipocalimab, an investigational treatment for early-onset severe hemolytic disease of the fetus and newborn (HDFN). The study met its primary endpoint, demonstrating a significant reduction in maternal IgG levels and prevention of hemolytic disease in newborns.

WEB IVIG is used in some cases of early-onset severe HDFN on the basis in part of its competitive FcRn inhibition which is similar to nipocalimab 28 but.

```